Alkermes
Alkermes plc, a leading biopharmaceutical company headquartered in Ireland, focuses on developing innovative therapies for central nervous system (CNS) disorders and addiction. Founded in 1987, Alkermes has established a strong presence in the global healthcare market, with significant operations in the United States and Europe.
The company is renowned for its unique drug delivery technologies and a robust portfolio of products, including treatments for schizophrenia, depression, and opioid dependence. Alkermes' commitment to addressing complex medical needs has positioned it as a key player in the biopharmaceutical industry, with notable achievements in advancing patient care through its proprietary formulations.
With a focus on scientific excellence and patient-centric solutions, Alkermes continues to drive innovation and improve outcomes for individuals affected by serious mental health conditions.
-16 vs industry average
Alkermes’s score of 22 is lower than 35% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Alkermes?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2026
Reported emissions
Scope 3 accounts for ••• of total emissions.
Alkermes's reported carbon emissions
In 2023, Alkermes, headquartered in Ireland (IE), reported total emissions of approximately 32,480,000 kg CO2e, comprising 15,753,000 kg CO2e from Scope 1 and 16,726,000 kg CO2e from Scope 2 emissions. The company has not disclosed any Scope 3 emissions data.
Over the past few years, Alkermes has shown a commitment to reducing its carbon footprint. In 2022, the total emissions were approximately 33,810,000 kg CO2e, indicating a slight reduction in 2023. However, there are currently no specific reduction targets or initiatives outlined in their climate commitments, such as those from the Science Based Targets initiative (SBTi).
Alkermes's emissions data is sourced directly from the company, with no cascading from a parent organization. The company continues to focus on transparency in its emissions reporting, as evidenced by its disclosures.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Alkermes’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Alkermes yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Alkermes
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project